The electrocardiographic signature of variant transthyretin amyloidosis
- PMID: 37852541
- PMCID: PMC10843784
- DOI: 10.1016/j.ijcard.2023.131442
The electrocardiographic signature of variant transthyretin amyloidosis
Conflict of interest statement
Declaration of Competing Interest None.
Figures

References
-
- Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al., Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association, Circulation. 142 (1) (2020) e7–e22. - PubMed
-
- Fontana M, Gilbertson J, Verona G, Riefolo M, Slamova I, Leone O, Rowczenio D, Botcher N, Ioannou A, Patel RK, Razvi Y, Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy, N. Engl. J. Med 388 (23) (2023. Jun 8) 2199–2201. - PubMed
-
- Russo D, Cappelli F, Di Bella G, Tini G, Porcari A, Cipriani A, et al., Electrocardiographic heterogeneity of patients with variant transthyretin amyloid cardiomyopathy: genotype-phenotype correlations, Int. J. Cardiol 131354 (2023). - PubMed
-
- Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al., Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, N. Engl. J. Med 379 (11) (2018) 1007–1016. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials